Journal of Clinical and Aesthetic Dermatology

MauiDerm 2017

An evidence-based, peer-reviewed journal for practicing clinicians in the field of dermatology

Issue link: http://jcadonline.epubxp.com/i/824994

Contents of this Issue

Navigation

Page 13 of 31

JCAD S14 journal of clinical and aesthetic dermatology JCAD journal of clinical and aesthetic dermatology May 2017 • Volume 10 • Number 5 (Supplement 1) i ncreased from baseline with both d oses of brodalumab relative to placebo (placebo: 5.1% and 3.7%; brodalumab 140mg: 33.8% and 30.9%; and brodalumab 210mg: 40.3% and 38.7%; P<0.0001). A combined analysis from the two Phase 3 studies with ustekinumab as the active comparator ( AMAGINE-2/-3) showed rapid improvements in response with brodalumab 140 and 210mg vs. ustekinumab at Week 2 (burning, 53.8% and 58.3% vs 38.3%; stinging, 53.3% and 59.4% vs 40.0%) that persisted with brodalumab 210mg treatment through Week 12 for both endpoints (P<0.05). Increases from baseline in the percentages of responders were also observed at Week 12 in AMAGINE-1/-2/- 3 (placebo: 9.5% and 6.2%; brodalumab 140mg: 52.1% and 49.4%; and brodalumab 210mg: 60.9% and 58.2%, for burning and stinging, respectively; P<0.0001 for both brodalumab doses vs. placebo in both endpoints). Conclusion: Brodalumab demonstrated rapid and robust improvements in patient-reported burning and stinging symptoms of psoriasis, and elicited better response rates than either placebo or ustekinumab. Financial diclosures/funding: This study was sponsored by Amgen Inc. Medical writing support was provided by MedThink SciCom and funded by Valeant Pharmaceuticals North America LLC. Disclosures: Lawrence Green has served as an investigator, consultant, or speaker for Amgen Inc; AbbVie, Inc; Celgene Corporation; Janssen Biotech, Inc; Merck & Co, Inc (MSD); Novartis Pharmaceuticals Corporation; and Valeant Pharmaceuticals North America LLC. Leon Kircik has served as an investigator, speaker, advisory board member, or consultant for A bbott Laboratories; Aclaris, Inc; A llergan, Inc; Amgen Inc; Anacor Pharmaceuticals, Inc; Assos Pharma; Astellas Pharma US, Inc; Asubio Pharma Co, Ltd; Berlex Laboratories (Bayer Healthcare Pharmaceuticals); Biogen-Idec, Inc; Biolife; Biopelle; Boehringer Ingelheim; Breckinridge P harma; Colbar; Celgene Corporation; Centocor, Inc; CollaGenex; Combinatrix; Connetics Corporation; Coria; Dermira, Inc; Dermik Laboratories; Dow Pharmaceutical Sciences, Inc; Dusa Pharmaceuticals, Inc; Embil Pharmaceutical Co, Ltd; Eli Lilly & Co; EOS; Ferndale Laboratories, Inc; Galderma Laboratories, LP; Genetech, Inc; GlaxoSmithKline, Plc; Health Point Ltd; Idera, Inc; Intendis, Inc; Innocutis Medical, LLC; Innovail; Johnson & Johnson; Laboratory Skin Care, Inc; Leo Pharma, Inc; L'Oreal SA; 3M; Maruho Co, Ltd; Medical International Technologies; Merck & Co, Inc; Medicis Pharmaceutical Corporation; Merz; Nano Bio Corporation; Novartis Pharmaceutical Corporation; Noven Pharmaceuticals, Inc; Nucryst Pharmaceuticals Corporation; Obagi Medical Products, Inc; Onset; OrthoNeutrogena; Promius Pharma, LLC; PediaPharma, Inc; QLT, Inc; PharmaDerm; Pfizer, Inc: PuraCap: Quinnova: Quatrix: Serono (Merck- Serono International SA): SkinMedica, Inc; Stiefel Laboratories, Inc; Sun Pharmaceutical Industries, Ltd; Taro; TolerRx, Inc; Triax; UCB, Inc; Valeant Pharmaceuticals North America LLC; Warner-Chilcott; XenoPort, Inc; and ZAGE. David Pariser has served as a consultant, advisory board member, or investigator for Abbott Laboratories; Amgen, Inc; Bickel Biotechnology; Biofrotera AG; Celgene Corporation; Dermira, Inc; DUSA Pharmaceuticals, Inc; Eli Lilly & Co; LEO Pharma Inc; Novartis Pharmaceuticals Corporation; N ovo Nordisk A/S; Ortho D ermatologics; Peplin, Inc; Pfizer, Inc; Photocure ASA; Promius Pharmaceuticals; Regeneron; Stiefel Laboratories, Inc; TheraVida; and Valeant Pharmaceuticals International. Shipra Rastogi and Robert J. Israel are employees of Valeant Pharmaceuticals N orth America LLC and may hold stock and/or stock options in the company. Radhakrishnan Pillai is an employee of Dow Pharmaceutical Sciences (a division of Valeant Pharmaceuticals North America LLC) and may hold stock and/or stock options in the company. Ease of Use and Confidence Using Auto-Injector to Administer Ixekizumab in a Phase 3 Trial Evaluated with Subcutaneous Administration Assessment Questionnaire (SQAAQ) Presenters: Jerry Bagel, 1 Kristina Callis Duffin, 2 Michael Bukhalo, 3 Margaret Bobonich, 4 Anne Gill, 5 Fangyi Zhao, 5 Beth A. Pangallo, 5 Catherine Shuler, 5 David Shrom, 5 Myriam Vincent 5 Affiliations: 1 Psoriasis Treatment Center of Central New Jersey, Windsor, NJ; 2 Department of Dermatology, University of Utah, Salt Lake City, UT; 3 Altman Dermatology Associates, Arlington Heights, IL; 4 Case Western Reserve University, Cleveland, OH; 5 Eli Lilly and Company, Indianapolis, IN Introduction: Many biologic agents are available as self-administered subcutaneous injections. In order for patients/caregivers to feel confident in their ability to administer therapy, an injection device should be easy to use. Ixekizumab (IXE) is a high-affinity monoclonal antibody that selectively targets interleukin-17A (IL-17A), approved for the treatment of psoriasis. The objective of this study was to report the usability and patient-

Articles in this issue

Archives of this issue

view archives of Journal of Clinical and Aesthetic Dermatology - MauiDerm 2017